Get the Stockscreener App
4.79
1.24%
-0.06
Molecular Partners Ag Adr stock is traded at $4.79, with a volume of 2,058.
It is down -1.24% in the last 24 hours and down -5.15% over the past month.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
See More
Previous Close:
$4.85
Open:
$4.6
24h Volume:
2,058
Relative Volume:
0.16
Market Cap:
$185.42M
Revenue:
$7.80M
Net Income/Loss:
$-69.02M
P/E Ratio:
-2.237
EPS:
-2.1413
Net Cash Flow:
$-66.61M
1W Performance:
-2.24%
1M Performance:
-5.15%
6M Performance:
-15.07%
1Y Performance:
+15.14%
1-Day Range:
$4.60
$5.05
1-Week Range:
$4.60
$5.05
52-Week Range:
$3.32
$12.70
Molecular Partners Ag Adr Stock (MOLN) Company Profile
Name
Molecular Partners Ag Adr
Sector
Industry
Phone
-
Address
-
Compare MOLN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MOLN
Molecular Partners Ag Adr
|
5.03 | 185.42M | 7.80M | -69.02M | -66.61M | -2.1413 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.11 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
688.45 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
632.13 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.19 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.67 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Molecular Partners Ag Adr Stock (MOLN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-30-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-29-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| May-25-22 | Upgrade | Credit Suisse | Underperform → Neutral |
| Apr-27-22 | Downgrade | Credit Suisse | Neutral → Underperform |
| Jul-13-21 | Initiated | Cowen | Outperform |
| Jul-12-21 | Resumed | SVB Leerink | Outperform |
View All
Molecular Partners Ag Adr Stock (MOLN) Latest News
Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call - GlobeNewswire Inc.
Wall Street Analysts Think Molecular Partners AG Sponsored ADR (MOLN) Could Surge 80.72%: Read This Before Placing a Bet - Yahoo Finance
Here's Why Seagate (STX) is a Strong Momentum Stock - Yahoo Finance
Molecular Partners backs FY24 total expenses view of of CHF 65M-CHF 70M - TipRanks
Molecular Partners, Orano Med announce presentation of MP0712 data - TipRanks
Molecular Partners expands 212Pb co-development agreement with Orano Med - TipRanks
Molecular Partners shares gain on Leerink's outperform rating - Investing.com
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Molecular Partners Shares Rise on Positive Trial Data for MP0317 - MarketWatch
U.S. shares mixed at close of trade; Dow Jones Industrial Average up 0.19% - Investing.com UK
US stock market gainers for the last week of April 2022 - Nairametrics
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move This High? - Yahoo Finance
Market Data Center - Barron's
Molecular Partners Ag Adr Stock (MOLN) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.34%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):